A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Terminated · Phase 2 · NCT04914897
Conditions: Pleural Mesothelioma, Non-small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $1,250
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 106
About the trial
- Sponsor
- Sanofi (with Merck Sharp & Dohme LLC)
- Tested
- THOR-707 (drug), Pembrolizumab (drug)
- Dates
- Started 2021-09-23; completion 2024-10-17
- Results posted
- Yes
The Primary Objective was: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. The Secondary Objectives were: * To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies. * To assess other indicators of antitumor activity. * To assess the pharmacokinetic (PK) profile of SAR444245 when given in combination with pembrolizumab. * To assess the immunogenicity of SAR444245.
From ClinicalTrials.gov, last updated 2025-10-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $1,250 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Inst LLC $1,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.